Article The Rockefeller University Press $30.00

Liver resection is an essential component of treatment for many patients with primary or secondary liver malignancies, but there is a finite amount of liver that can be removed (70%) to avoid deficient regeneration and liver dysfunc-tion (Helling, 2006; Breitenstein et al., 2009; Garcea and Maddern, 2009). Liver regeneration is also important for both donors and recipients of small-for-size liver grafts, a type of surgery which could significantly increase the donor pool but which is not widely performed pri-marily due to concerns of morbidity and mor-tality in donors (Clavien et al., 2007). Other than utilization of liver support systems, there is cur-rently no therapy for patients with a failing remnant or small-for-size liver, and there is a sig-nificant need for strategies that can enhance the regenerative capacity of livers and increase the amount of liver that can be safely resected. Impaired liver regeneration is associated with the extent of ischemia reperfusion injury (IRI), an unavoidable component of transplan-tation surgery and a component of most liver resection surgeries. Thus, ameliorating postsur-gical hepatic IRI may enhance the regenerative capacity of the liver. Although currently there is no approved treatment for IRI, complement inhibition is recognized as a potential therapeu-tic strategy for reducing IRI (Diepenhorst et al., 2009) because complement plays a key role in post-ischemic inflammation and injury. How-ever, complement activation products also play a critical role in liver regeneration (Mastellos et al.